Literature DB >> 23245311

Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships.

Paolo Polucci1, Paola Magnaghi, Mauro Angiolini, Daniela Asa, Nilla Avanzi, Alessandra Badari, Jay Bertrand, Elena Casale, Silvia Cauteruccio, Alessandra Cirla, Liviana Cozzi, Arturo Galvani, Peter K Jackson, Yichin Liu, Steven Magnuson, Beatrice Malgesini, Stefano Nuvoloni, Christian Orrenius, Federico Riccardi Sirtori, Laura Riceputi, Simona Rizzi, Beatrice Trucchi, Tom O'Brien, Antonella Isacchi, Daniele Donati, Roberto D'Alessio.   

Abstract

Valosine containing protein (VCP), also known as p97, is a member of AAA ATPase family that is involved in several biological processes and plays a central role in the ubiquitin-mediated degradation of misfolded proteins. VCP is an ubiquitously expressed, highly abundant protein and has been found overexpressed in many tumor types, sometimes associated with poor prognosis. In this respect, VCP has recently received a great deal of attention as a potential new target for cancer therapy. In this paper, the discovery and structure-activity relationships of alkylsulfanyl-1,2,4-triazoles, a new class of potent, allosteric VCP inhibitors, are described. Medicinal chemistry manipulation of compound 1, identified via HTS, led to the discovery of potent and selective inhibitors with submicromolar activity in cells and clear mechanism of action at consistent doses. This represents a first step toward a new class of potential anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23245311     DOI: 10.1021/jm3013213

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

Authors:  Paola Magnaghi; Roberto D'Alessio; Barbara Valsasina; Nilla Avanzi; Simona Rizzi; Daniela Asa; Fabio Gasparri; Liviana Cozzi; Ulisse Cucchi; Christian Orrenius; Paolo Polucci; Dario Ballinari; Claudia Perrera; Antonella Leone; Giovanni Cervi; Elena Casale; Yang Xiao; Chihunt Wong; Daniel J Anderson; Arturo Galvani; Daniele Donati; Tom O'Brien; Peter K Jackson; Antonella Isacchi
Journal:  Nat Chem Biol       Date:  2013-07-28       Impact factor: 15.040

Review 2.  Targeting the unfolded protein response in disease.

Authors:  Claudio Hetz; Eric Chevet; Heather P Harding
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

3.  Degradation of the deubiquitinating enzyme USP33 is mediated by p97 and the ubiquitin ligase HERC2.

Authors:  Nickie C Chan; Willem den Besten; Michael J Sweredoski; Sonja Hess; Raymond J Deshaies; David C Chan
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

4.  Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97.

Authors:  Celeste Alverez; Michelle R Arkin; Stacie L Bulfer; Raffaele Colombo; Marina Kovaliov; Matthew G LaPorte; Chaemin Lim; Mary Liang; William J Moore; R Jeffrey Neitz; Yongzhao Yan; Zhizhou Yue; Donna M Huryn; Peter Wipf
Journal:  ACS Med Chem Lett       Date:  2015-10-23       Impact factor: 4.345

5.  Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway.

Authors:  Celeste Alverez; Stacie L Bulfer; Ramappa Chakrasali; Michael S Chimenti; Raymond J Deshaies; Neal Green; Mark Kelly; Matthew G LaPorte; Taber S Lewis; Mary Liang; William J Moore; R Jeffrey Neitz; Vsevolod A Peshkov; Michael A Walters; Feng Zhang; Michelle R Arkin; Peter Wipf; Donna M Huryn
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

6.  Evaluating p97 inhibitor analogues for their domain selectivity and potency against the p97-p47 complex.

Authors:  Chen-Jie Fang; Lin Gui; Xiaoyi Zhang; Derek R Moen; Kelin Li; Kevin J Frankowski; Henry J Lin; Frank J Schoenen; Tsui-Fen Chou
Journal:  ChemMedChem       Date:  2014-11-06       Impact factor: 3.466

7.  VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.

Authors:  Prabhakar Bastola; Lisa Neums; Frank J Schoenen; Jeremy Chien
Journal:  Mol Oncol       Date:  2016-09-28       Impact factor: 6.603

8.  Altered cofactor regulation with disease-associated p97/VCP mutations.

Authors:  Xiaoyi Zhang; Lin Gui; Xiaoyan Zhang; Stacie L Bulfer; Valentina Sanghez; Daniel E Wong; YouJin Lee; Lynn Lehmann; James Siho Lee; Pei-Yin Shih; Henry J Lin; Michelina Iacovino; Conrad C Weihl; Michelle R Arkin; Yanzhuang Wang; Tsui-Fen Chou
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

9.  Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains.

Authors:  Tsui-Fen Chou; Stacie L Bulfer; Conrad C Weihl; Kelin Li; Lev G Lis; Michael A Walters; Frank J Schoenen; Henry J Lin; Raymond J Deshaies; Michelle R Arkin
Journal:  J Mol Biol       Date:  2014-05-27       Impact factor: 5.469

10.  2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition.

Authors:  Soojay Banerjee; Alberto Bartesaghi; Alan Merk; Prashant Rao; Stacie L Bulfer; Yongzhao Yan; Neal Green; Barbara Mroczkowski; R Jeffrey Neitz; Peter Wipf; Veronica Falconieri; Raymond J Deshaies; Jacqueline L S Milne; Donna Huryn; Michelle Arkin; Sriram Subramaniam
Journal:  Science       Date:  2016-01-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.